Cargando…

Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report

Triple-negative breast cancer is the most aggressive subtype of mammary carcinoma. In the early stage, neoadjuvant chemotherapy (NAC) is the standard of care for prognostic stratification and the best adjuvant treatment strategy. A 30-year-old female presented in the emergency room because of a giga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez-Puerto, Diego, Llop-Guevara, Alba, Cruellas, Mara, Torres-Esquius, Sara, De La Torre, Javier, Peg, Vicente, Balmaña, Judith, Pimentel, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516106/ https://www.ncbi.nlm.nih.gov/pubmed/36185283 http://dx.doi.org/10.3389/fonc.2022.963728

Ejemplares similares

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
por: Pellegrino, Benedetta, et al.
Publicado: (2019)

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
por: Pellegrino, B., et al.
Publicado: (2020)

Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair
por: Ratner, Elena S, et al.
Publicado: (2016)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

FZD5 contributes to TNBC proliferation, DNA damage repair and stemness
por: Sun, Yu, et al.
Publicado: (2020)

Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
por: Chai, Yue, et al.
Publicado: (2022)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
por: Li, Junjun, et al.
Publicado: (2022)

Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes
por: Emelyanova, Marina, et al.
Publicado: (2022)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
por: Tsang, Erica S., et al.
Publicado: (2023)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC
por: Malfatti, Matilde Clarissa, et al.
Publicado: (2019)

Leveraging homologous recombination repair deficiency in sarcoma
por: Slade, Dea, et al.
Publicado: (2023)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023)

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
por: Provenzano, Leonardo, et al.
Publicado: (2023)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023)

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
por: Wen, Hao, et al.
Publicado: (2022)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

LC–MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells
por: Estrada-Pérez, Alan Rubén, et al.
Publicado: (2022)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Leveraging MYC as a therapeutic treatment option for TNBC
por: Carey, Jason P.W., et al.
Publicado: (2018)

Optimization of Short RNA Aptamers for TNBC Cell Targeting
por: Camorani, Simona, et al.
Publicado: (2022)

Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells
por: Consoli, Valeria, et al.
Publicado: (2022)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
por: Carroll, Natalie, et al.
Publicado: (2022)

An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC
por: Zhang, Mengqi, et al.
Publicado: (2023)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors()
por: Shi, Yaqin, et al.
Publicado: (2019)

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
por: Pacheco-Barcia, Vilma, et al.
Publicado: (2022)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
por: Wang, Yifan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_004in0ljrditej2c75o15vfpmu